^
    Back
    Association details:
    Biomarker:High NLR
    Cancer:Hepatocellular Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    Tecentriq (atezolizumab) (PD-L1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    989P - Disease etiology and efficacy outcomes with atezolizumab plus bevacizumab (atezo-bev) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Multinational retrospective analysis

    Published date:
    10/16/2023
    Excerpt:
    In the multivariable analysis, higher baseline NLR (≥2.5 [median]) was significantly associated with poorer PFS (median 3.8 vs 9.5 mo, HR 2.2, p=0.003) and OS (median 8.8 vs 27.0 mo, HR 5.0, p<0.001) compared to baseline NLR < 2.5.
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Nihon Shokakibyo Gakkai Zasshi
    Title:

    [Significance of neutrophil-to-lymphocyte ratio in atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma]

    Published date:
    10/12/2023
    Excerpt:
    This study aimed to investigate the significance of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor by reporting 21 patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atezo/Bev) as the first line of treatment....The high NLR group demonstrated a shorter PFS than the low NLR group.
    DOI:
    10.11405/nisshoshi.120.837